(Q37905686)

25 August 2017

1 reference

title

Severe asthma with fungal sensitization (English)

1 reference

25 August 2017

0 references

1

1 reference

25 August 2017

language of work or name

1 reference

1 October 2011

1 reference

Current Allergy and Asthma Reports

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

403-413

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-011-0217-4

25 August 2017

exact match

0 references

cites work

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Asthma severity and medical resource utilisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Exposure and sensitization to indoor allergens: association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

High frequency of atopic asthma in a pulmonary clinic population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Atopic status in patients with brittle and non-brittle asthma: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

The link between fungi and severe asthma: a summary of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Severe asthma and fungi: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

New Orleans asthma. V. Relationship between Charity Hospital asthma admission rates, semiquantitative pollen and fungal spore counts, and total particulate aerometric sampling data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Effect of environmental molds on risk of death from asthma during the pollen season.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

The effect of outdoor fungal spore concentrations on daily asthma severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Fungal and other spore counts as predictors of admissions for asthma in the Trent region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Invited Commentary: Is Indoor Mold Exposure a Risk Factor for Asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

A comparison of the prevalence of sensitization to antigens among asthmatics in Cleveland and London

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Specific IgE response to trichophyton and asthma severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

An alternate method of classifying allergic bronchopulmonary aspergillosis based on high-attenuation mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Interleukin-5 modulates eosinophil accumulation in allergic guinea pig lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Cystic fibrosis transmembrane conductance regulator gene mutations: do they play a role in the aetiology of allergic bronchopulmonary aspergillosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Polymorphisms in Toll‐Like Receptor Genes and Susceptibility to Pulmonary Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

CHIT1 mutations: genetic risk factor for severe asthma with fungal sensitization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Severe asthma with fungal sensitization in a child: response to itraconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Cytokines and chemokines in allergic bronchopulmonary aspergillosis (ABPA) and experimental Aspergillus-induced allergic airway or asthmatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Relative reactivity ofAspergillusallergens used in serological tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Omalizumab for treatment of ABPA exacerbations in CF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Life-threatening allergic bronchopulomnary aspergillosis treated with methylprednisolone and anti-IgE monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Itraconazole suppresses an elicitation phase of a contact hypersensitivity reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Adverse events associated with itraconazole in 189 patients on chronic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Allergic Bronchopulmonary Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Epidemiology of Allergic Bronchopulmonary Aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Aspergillushypersensitivity in patients with chronic obstructive pulmonary disease: COPD as a risk factor for ABPA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-011-0217-4

Allergic bronchopulmonary aspergillosis: lessons learnt from genetics

21 January 2018

1 reference

12 December 2020

Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society

1 reference

12 December 2020

Automated specific IgE assay with recombinant allergens: evaluation of the recombinant Aspergillus fumigatus allergen I in the Pharmacia Cap System

1 reference

12 December 2020

Serum IgE and IgG antibody activity against Aspergillus fumigatus as a diagnostic aid in allergic bronchopulmonary aspergillosis

1 reference

12 December 2020

Non-aspergillus allergic bronchopulmonary mycosis in a pediatric patient with cystic fibrosis

1 reference

12 December 2020

Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital

1 reference

12 December 2020

Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis

1 reference

12 December 2020

Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis

1 reference

12 December 2020

Is the SMART approach better than other treatment approaches for prevention of asthma exacerbations? A meta-analysis

1 reference

12 December 2020

1 reference

12 December 2020

Azoles for allergic bronchopulmonary aspergillosis associated with asthma

1 reference

12 December 2020

Fungus Spores, Air Pollutants, and Other Determinants of Peak Expiratory Flow Rate in Children

1 reference

12 December 2020

A new look at the natural history of Aspergillus hypersensitivity in asthmatics

1 reference

12 December 2020

Immunologic significance of a collagen-derived culture filtrate containing proteolytic activity in Aspergillus-related diseases

1 reference

12 December 2020

The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program

1 reference

12 December 2020

Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells

1 reference

12 December 2020

Treatment of late-onset asthma with fluconazole

1 reference

12 December 2020

Importance of house dust mite and Alternaria allergens in childhood asthma: an epidemiological study in two climatic regions of Australia

1 reference

12 December 2020

Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines

1 reference

12 December 2020

Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice

1 reference

12 December 2020

Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study

1 reference

12 December 2020

Association between sensitization to Aureobasidium pullulans (Pullularia sp) and severity of asthma

1 reference

12 December 2020

Anti-IgE for chronic asthma in adults and children

1 reference

12 December 2020

Incidence of immediate sensitivity to Aspergillus fumigatus in a North American asthmatic population

1 reference

12 December 2020

Infectious-allergic bronchopulmonary paecilomycosis

1 reference

12 December 2020

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

1 reference

12 December 2020

Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis

1 reference

12 December 2020

Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells

1 reference

12 December 2020

Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole

1 reference

12 December 2020

British Guideline on the Management of Asthma

1 reference

12 December 2020

Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA

1 reference

12 December 2020

[Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis]

1 reference

12 December 2020

Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.

1 reference

12 December 2020

Sensitivity to fungal allergens is a risk factor for life-threatening asthma

1 reference

12 December 2020

The effects of itraconazole on the immune responses in ICR mice

1 reference

12 December 2020

ABPA or AFAA: That Is the Question

1 reference

12 December 2020

Seasonal and recurrent intensive care unit admissions for acute severe asthma in children

1 reference

12 December 2020

Mold-sensitivity in children with moderate-severe asthma is associated with HLA-DR and HLA-DQ

1 reference

12 December 2020

Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis.

1 reference

12 December 2020

HLA-DR polymorphism in allergic bronchopulmonary aspergillosis

1 reference

12 December 2020

Comparison of the skin test and ImmunoCAP system in the evaluation of mold allergy

1 reference

12 December 2020

The possible role of aero‐allergens in the epidemic of asthma deaths

1 reference

12 December 2020

The anti-fungal agent itraconazole exerts immunosuppressive effects on alloreactivity but not on natural immunity in vitro

1 reference

12 December 2020

Allergic bronchopulmonary aspergillosis: a retrospective study of 35 cases

1 reference

12 December 2020

The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone

1 reference

12 December 2020

10.1007/S11882-011-0217-4

Identifiers

DOI

1 reference

25 August 2017

1 reference